Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hofseth BioCare ASA's enterprise value is $94.07 Mil.
Hofseth BioCare ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.23 Mil. Therefore, Hofseth BioCare ASA's EV-to-EBITDA for today is -13.01.
The historical rank and industry rank for Hofseth BioCare ASA's EV-to-EBITDA or its related term are showing as below:
HOFBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.99 Med: -15.08 Max: 89.21
Current: -13.67
During the past 13 years, the highest EV-to-EBITDA of Hofseth BioCare ASA was 89.21. The lowest was -68.99. And the median was -15.08.
HOFBF's EV-to-EBITDA is ranked worse than 100% of 1644
companies
in the Consumer Packaged Goods industry
Industry Median: 9.035
vs HOFBF: -13.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hofseth BioCare ASA's PE Ratio (TTM) for today is calculated as:
Hofseth BioCare ASA's share price for today is $0.1666.
Hofseth BioCare ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.034.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Hofseth BioCare ASA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Hofseth BioCare ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hofseth BioCare ASA EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Hofseth BioCare ASA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hofseth BioCare ASA's EV-to-EBITDA falls into.
Hofseth BioCare ASA's current Enterprise Value is $94.07 Mil.
Hofseth BioCare ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hofseth BioCare ASA (HOFBF) has a EV-to-EBITDA of -13.01 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hofseth BioCare ASA. According to the industry distribution chart, Hofseth BioCare ASA ranks #999999 out of 1644 companies in the Consumer Packaged Goods industry.
Is Hofseth BioCare ASA's EV-to-EBITDA too high?
Hofseth BioCare ASA's current EV-to-EBITDA is -13.01. Based on the distribution chart, Hofseth BioCare ASA ranks #999999 out of 1644 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Hofseth BioCare ASA has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Hofseth BioCare ASA's EV-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Hofseth BioCare ASA ranks #999999 out of 1644 companies for EV-to-EBITDA. This places Hofseth BioCare ASA in the lower half of its industry. The industry median EV-to-EBITDA is 9.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.04, based on 1,644 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hofseth BioCare ASA. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hofseth BioCare ASA's current EV-to-EBITDA is -13.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hofseth BioCare ASA stock overvalued right now?
Hofseth BioCare ASA (HOFBF) has a current EV-to-EBITDA of -13.01. The stock's GF Value™ is $0.26, compared to a current price of $0.17 — trading 35.9% below its estimated fair value. The current EV-to-EBITDA is -13.01. Hofseth BioCare ASA's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hofseth BioCare ASA (HOFBF), the current EV-to-EBITDA is -13.01 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hofseth BioCare ASA (HOFBF) Overvalued in 2026?
Based on GuruFocus' analysis, Hofseth BioCare ASA stock appears to be undervalued.
The current stock price of $0.17 is trading 35.9% below its estimated GF Value™ of $0.26.
Key valuation signals for HOFBF:
EV-to-EBITDA: -13.01
GF Value™: $0.26 vs. price of $0.17 (35.9% below fair value)
No single metric tells the full story. See the HOFBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hofseth BioCare ASA is a Norway-based company engaged in the business of developing, manufacturing, marketing, and selling marine ingredients such as oil, calcium, and protein products. Its brands, which also generate revenue, include salmon oil (OmeGo), water-soluble protein (ProGo), calcium/collagen (CalGo and NT-II), and non-soluble protein (PetGo), all of which are produced in the Midsund plant. The firm sells its products to various segments of the human nutrition market, such as sports nutrition, supplements, and health foods, as well as to the market within nutrition for the pet and feed industry. Geographically, the company generates maximum revenue from Europe, followed by North America and Asia.
51GF Score
Get the complete analysis for HOFBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOFBF has been successfully added to your 
